公开(公告)号：US20080039499A1

公开(公告)日：2008-02-14

申请号：US11628318

申请日：2005-05-31

申请人： Justin Bower ,  Gordon Hamlin ,  Jon Winter

发明人： Justin Bower ,  Gordon Hamlin ,  Jon Winter

IPC分类号： C07D417/12 ,  A61K31/426 ,  A61K31/445 ,  A61K31/4535 ,  C07D417/14 ,  A61K31/454 ,  A61P29/00 ,  C07D277/38

CPC分类号： C07D417/14 ,  C07D417/12

摘要： The use of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein R1, Ra, R8, R2, R3 and R4 are as defined in the specification, in the preparation of a medicament for the treatment of C—C chemokine mediated conditions. Novel compounds of formula (I) and pharmaceutical compositions containing them are also described and claimed.

摘要翻译： 使用式（I）化合物或其药学上可接受的盐或溶剂合物，其中R 1，R 2，R 8， R 2，R 3和R 4如本说明书中所定义，用于制备用于治疗CC趋化因子介导的病症的药物 。 还描述和要求保护新的式（I）化合物和含有它们的药物组合物。

公开(公告)号：US20070244133A1

公开(公告)日：2007-10-18

申请号：US11628449

申请日：2005-05-31

申请人： Justin Bower ,  Alan Faull ,  Jon Winter

发明人： Justin Bower ,  Alan Faull ,  Jon Winter

IPC分类号： A61K31/519 ,  A61P1/00 ,  A61P11/00 ,  A61P17/06 ,  A61P35/00 ,  C07D239/70 ,  C07D495/04 ,  C07D513/04

CPC分类号： C07D495/04 ,  A61K31/519 ,  C07D513/04

摘要： The use of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein X1, X2, X3, X4, Ra, p, R1, Z, Y, R2, R3 and R4 are as defined in the specification, in the preparation of a medicament for the treatment of C—C chemokine mediated conditions, such as inflammatory disease. Certain compounds of formula (I) are novel and these, together with their preparation are also described and claimed.

摘要翻译： 使用式（I）化合物或其药学上可接受的盐或溶剂合物，其中X 1，X 2，X 3， R 4，R 9，R 11，R 12，R 12， 3和R 4如本说明书中所定义，用于制备用于治疗CC趋化因子介导的病症例如炎性疾病的药物。 某些式（I）化合物是新颖的，并且这些化合物及其制备方法也被描述和要求保护。

公开(公告)号：US20070179161A1

公开(公告)日：2007-08-02

申请号：US10551177

申请日：2004-03-18

申请人： Martin Parratt ,  Justin Bower ,  Douglas Williamson ,  Andrew Cansfield

发明人： Martin Parratt ,  Justin Bower ,  Douglas Williamson ,  Andrew Cansfield

IPC分类号： A61K31/519 ,  C07D487/02

CPC分类号： C07D487/04 ,  A61K31/519

摘要： Compounds of formula (I) or salts, N-oxides, hydrates or solvates thereof are inhibitors of kinase activity, and useful for the treatment of, for example, cancer, psoriasis or restenosis: wherein ring A is an optionally substituted carbocyclic or heterocyclic radical. Alk represents an optionally substituted divalent C1-C6 alkylene radical. n is 0 or 1. Q represents a radical of formula -(Alk1)p (X)r-(Alk2)s-Z wherein in any compatible combination Z is hydrogen or an optionally substituted carbocyclic or heterocyclic ring; Alk1 and Alk2 are optionally substituted divalent C1-C6 alkylene radicals which may contain a —O—, —S— or —NRA— link, wherein RA is hydrogen or C1-C6 alkyl; X represents —O—, —S—, —(C═O)—, —(C═S)—, —SO2—, —SO—, —C(═O)O—, —OC(═O)—, —C(═O)NRA—, —NR AC(═O)—, —C(═S)NRA, —NRAC(═S)—, —SO2NRA—, —NRASO2—, —OC(═O)NRA—, —NRAC(═O)O—, or —NRA— wherein RA is hydrogen or C1-C6 alkyl. p, r and s are independently 0 or 1. R1 represents a radical -(Alk3)a-(Y)b-(Alk4)d-B wherein a, b and d are independently 0 or 1; Alk3 and Alk4 are optionally substituted divalent C,-C3 alkylene radicals; Y represents a monocyclic divalent carbocyclic or heterocyclic radical having from 5 to 8 ring atoms, —O—, —S—, or —NRA— wherein RA is hydrogen or C1-C6 alkyl; B represents hydrogen or halo, or an optionally substituted monocyclic carbocyclic or heterocyclic ring having from 5 to 8 ring atoms, or in the case where Y is —NRA— and b is 1, then RA and the radical -(Alk4)d-B taken together with the nitrogen to which they are attached may form an optionally substituted heterocyclic ring. R represents hydrogen, halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylthio, phenyl, benzyl, cycloalkyl with 3 to 6 ring atoms, or a monocyclic heterocyclic group having 5 or 6 ring atoms.

公开(公告)号：US20070275961A1

公开(公告)日：2007-11-29

申请号：US10558694

申请日：2004-06-02

申请人： Justin Bower ,  Andrew Cansfield ,  Allan Jordan ,  Martin Parratt ,  Lee Walmsley ,  Douglas Williamson

发明人： Justin Bower ,  Andrew Cansfield ,  Allan Jordan ,  Martin Parratt ,  Lee Walmsley ,  Douglas Williamson

IPC分类号： A61K31/519 ,  A61K31/496 ,  A61K31/5377 ,  A61P17/06 ,  A61P35/00 ,  A61P9/00 ,  C07D413/14 ,  C07D487/04

CPC分类号： A61K31/519 ,  C07D487/04

摘要： Compounds of formula (IA) or (AB) are kinase inhibitors, especially of CDK2, and/or PDK1 and/or CHK1: wherein Ring A is an optionally substituted aryl, heteroaryl, carbocyclic or heterocyclic radical, Alk represents an optionally substituted clivaient C1-C6 alkylene radical; n is 0 or 1; Q represents a radical of formula -(Alk1)p-(X),(Alk2)s-Z wherein in any compatible combination Z is hydrogen or an optionally substituted carbocyclic or heterocyclic ring, p, r and s are 0 or 1, and Alk1, Alk2, X, are as described in the specification, and R1 represents a radical 3 4 3 (CYC)k-(Alk3)a-(Y)b-(Alk4)d-B wherein k, a, b and d are 0 or 1, and Cyc, Alk3, Alk4 and B are as described in the specification.

摘要翻译： 式（IA）或（AB）的化合物是激酶抑制剂，特别是CDK2和/或PDK1和/或CHK1的激酶抑制剂：其中环A是任选取代的芳基，杂芳基，碳环或杂环基，Alk表示任选取代的亲水性C C 1 -C 6亚烷基; n为0或1; Q表示式 - （Alk-1）对 - （X），（Alk 2 O 3）-SZ的基团，其中以任何相容的组合 Z是氢或任选取代的碳环或杂环，p，r和s是0或1，并且Alk 1，Alk 2 X，如 规格，R 1表示基团3 4 3（CYC）3 - （烷基） （Y）b - 其中k，a，b和d分别为0或1，并且Cyc，Alk 3号，3号，4号和B号如说明书中所述。